GNI Group

Basic Information

Stock Code
2160
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
November 2001
Listing Year
August 2007
Official Website
https://www.gnipharma.com/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Heartseed, AnGes, Nexel Pharma, PeptiDream, SanBio, Helios, Rena Science, QualiPs, Takara Bio, Cover, QPS Institute, Japan Tissue Engineering

Overview

GNI Group is a pharmaceutical drug discovery company founded in 2001, with its main base in China, handling everything from new drug development to manufacturing and sales, making it a stock of note in the industry.

Current Situation

GNI Group recorded consolidated sales of 23.6 billion yen and net assets of approximately 39.7 billion yen for the fiscal year ending December 2024, establishing a strong presence mainly in the Chinese market as a drug discovery company. It has multiple pipelines in clinical trials, including the idiopathic pulmonary fibrosis treatment 'Aisuluyi.' It has established competitiveness through a vertically integrated model of new drug exploration, clinical development, manufacturing, and sales centered on China. It operates subsidiaries in the US and Hong Kong, expanding its business internationally. It is actively investing in technology development, with ongoing development of the pirfenidone derivative F351 for liver fibrosis treatment in both China and the US. It focuses on sustainability and corporate governance, with strategies centered on long-term growth and new drug approvals. In the future, further expansion into global markets and pipeline enhancement are expected to accelerate growth.

Trivia

Interesting Facts

  • Deploys the only idiopathic pulmonary fibrosis treatment drug sold in China
  • One of the few drug discovery companies holding development rights in multiple countries including the US and Hong Kong
  • Developed proprietary foam formulation technology enabling temperature control
  • Global company with many subsidiaries in Asia and North America
  • Pirfenidone derivative 'F351' is a notable pipeline in overseas clinical trials
  • Differentiates from competitors with vertically integrated model from clinical development to manufacturing and sales
  • Equity-method affiliate IriSys, LLC specializes in pharmaceutical manufacturing outsourcing and development
  • Shanghai Genomics specializes in genome-related reagent development
  • Experience developing acute promyelocytic leukemia treatment through joint venture with Toko Pharmaceutical
  • Enhances competitiveness through rapid clinical trial approvals and trial starts
  • High industry evaluation for speed of new drug approvals in China
  • GNI brand gradually expanding recognition in China's biopharma drug discovery field
  • Strength in forming pipelines covering diverse disease areas
  • International scientists placed at the core of the R&D team
  • Conducting drug development specialized for Asian markets using proprietary technologies

Hidden Connections

  • Corporate collaboration realizing technology transfer from Japan through joint venture with Toko Pharmaceutical
  • Global strategy entering the North American market through multiple US subsidiaries
  • Shanghai Genomics in China serves as the main production base for genome analysis reagents
  • Equity-method affiliate IriSys, LLC is a partner in advanced formulation technology
  • Exclusive agreement with AFT Pharmaceuticals in Southeast Asia including Asian markets
  • Proprietary foam formulation technology features rare temperature control in pharmaceuticals
  • Direct transactions with numerous Chinese medical institutions enabling rapid market deployment
  • Close collaboration with Chinese regulatory authorities in new drug approval processes

Future Outlook

Growth Drivers

  • Expansion of pharmaceutical demand and policy support in the Chinese market
  • Expansion of launches for innovative anti-fibrotic treatments
  • Success in international pipeline development and approvals
  • Competitive advantage through integrated system from clinical development to sales
  • Expansion of new drug discovery areas applying gene analysis technology
  • Aggressive global market expansion strategy
  • Increasing demand for chronic disease treatments due to aging society
  • Product deployment covering diverse disease areas
  • Response to technological advances in biopharmaceuticals
  • Rapid trials through good relations with regulatory authorities
  • Expansion of R&D digitalization and AI utilization
  • Strengthening of technology and market access through strategic partnerships

Strategic Goals

  • Market approval and commercialization of key pipelines
  • Achieve over 50% share in China and Asia markets
  • Expand global sales to 100 billion yen scale
  • Achieve international standards in sustainability management
  • Lead new drug development with advanced gene drug discovery technology
  • Diversification of revenue base through multi-country expansion
  • Innovation in R&D system and efficiency through AI utilization
  • Strengthening environmental impact reduction and social contribution activities
  • Expansion of clinical development outsourcing business
  • Improvement in formulation technology corresponding to diverse disease areas

Business Segments

Pharmaceutical Manufacturing and Sales

Overview
Core business including pharmaceutical manufacturing and sales, mainly centered on the Chinese market.
Competitiveness
Integrated development, manufacturing, and sales system
Customers
  • Chinese Medical Institutions
  • Pharmaceutical Wholesalers
  • Pharmacies and Drugstores
  • Export Agents
  • Research Institutions
  • Major Pharmaceutical Companies
  • Hospitals and Clinics
  • Biotechnology Companies
  • Regulatory Consulting Firms
  • Government Regulatory Agencies
Products
  • Idiopathic Pulmonary Fibrosis Treatment
  • Liver Fibrosis Treatment
  • Acute Liver Failure Treatment
  • Acute Promyelocytic Leukemia Treatment
  • Foam Topical Drugs
  • Clinical Trial Pharmaceuticals
  • Drug Discovery Pipeline Products
  • Anti-Fibrotic Drugs
  • Imported Drugs
  • Clinical Trial Drug Manufacturing

Gene Analysis Products and Research Support

Overview
Business area providing gene analysis-related products and technical support for drug discovery and research.
Competitiveness
Provision of advanced genome technology and high-quality reagents
Customers
  • University Research Institutions
  • Pharmaceutical Company R&D Departments
  • Bio Laboratories
  • Clinical Research Centers
  • Healthcare Companies
  • Gene Analysis Service Companies
  • Public Research Institutions
  • Pharmaceutical Development Support Companies
  • Medical Device Manufacturers
Products
  • Gene Analysis Reagents
  • DNA Microarray
  • Cell Analysis Kits
  • Genome Editing-Related Reagents
  • Molecular Diagnostic Reagents
  • Research Reagent Kits
  • Bioinformatics Tools

Clinical Development Outsourcing Services

Overview
Provides comprehensive outsourcing services in clinical development to support pharmaceutical companies' new drug launches.
Competitiveness
Clinical trial network centered on China and Asia
Customers
  • Pharmaceutical Manufacturers
  • Bio Ventures
  • Clinical Trial Institutions
  • R&D Institutions
  • Regulatory Authorities
  • Clinical Trial Recruitment Companies
  • Medical Device Development Companies
  • Pharmaceutical Manufacturing Outsourcing Companies
Products
  • Clinical Trial Monitoring
  • Clinical Trial Data Analysis
  • Manufacturing Outsourcing
  • Clinical Trial Application Support
  • Regulatory Consulting
  • Clinical Research Management

Medical Devices and Diagnostic Systems

Overview
Through related subsidiaries, manufactures and sells medical devices and provides pathology diagnostic systems.
Competitiveness
High technological capability in medical device development
Customers
  • Hospitals
  • Diagnostic Labs
  • Medical Device Distributors
  • Research Institutes
  • Diagnostic Software Companies
Products
  • Medical Devices
  • Pathology Diagnostic Systems
  • Analysis Software
  • Diagnostic Reagents

Competitive Advantage

Strengths

  • Strong development, manufacturing, and sales system centered on the Chinese market
  • New drug development capabilities through diverse pipelines
  • Drug discovery support capabilities utilizing gene analysis technology
  • Global subsidiary network
  • Integrated provision of clinical trials and manufacturing outsourcing services
  • High technological expertise and specialized R&D system
  • Track record of rapid approvals and market entry
  • Product lineup covering diverse disease areas
  • Technology acquisition through strategic partnerships
  • Strength in building clinical trial networks
  • Global responsiveness with trials in both the US and China
  • Research efficiency through bioinformatics utilization
  • Synergy effects with equity-method affiliates
  • Multi-layered product development pipeline
  • Advancement of clinical development tailored to market needs

Competitive Advantages

  • Vertically integrated new drug development and sales with China as the main base
  • Possession of advanced treatment pipelines such as for liver fibrosis and pulmonary fibrosis
  • Acquisition of development rights in diverse markets (China, US, Hong Kong, etc.)
  • Ability to provide integrated services from clinical development to manufacturing and sales
  • Superiority in biopharma drug discovery armed with gene analysis technology
  • Multi-country pipeline development system utilizing subsidiaries
  • Establishment of highly specialized R&D team
  • Accelerated development through rapid clinical trial approvals and pilot tests
  • Clear differentiation from competitors through enriched clinical-stage assets
  • Global regulatory compliance and market access capabilities
  • Possession of temperature-controlled foam formulation successful in development
  • Expansion of pharmaceutical portfolio across diverse disease areas
  • Strengthened revenue base through exclusive sales agreements in multiple regions
  • Enhanced technology sharing and collaboration among group subsidiaries
  • Building brand power in the international pharmaceutical market

Threats

  • Impact from changes in pharmaceutical regulations in China and overseas
  • Market entry of similar treatments by competitors
  • Uncertainty in clinical trial results and approval delays
  • Risks to overseas business from political and economic fluctuations
  • Intensified competition due to IP infringement and counterfeit products
  • Impact of exchange rate fluctuations on revenue
  • Increasing R&D costs and funding challenges
  • Growth slowdown risk from pipeline development delays
  • Delays in responding to rapid changes in market needs and medical technologies
  • Competition for talent in global competition
  • Difficulty in securing supply chain stability
  • Risk concentration from business dependent on specific countries

Innovations

2024: Phase 3 Clinical Trial for Expansion of Aisuluyi Indication to CTD-ILD

Overview
Conducting Phase 3 clinical trials in China for interstitial lung diseases other than idiopathic pulmonary fibrosis.
Impact
Contributes to indication expansion and increased market share.

2023: Start of First Phase 1 Clinical Trial for F351 in the US

Overview
Accelerating global expansion by starting clinical trials for liver fibrosis treatment drug F351 in the US.
Impact
Strengthens international development system and builds foundation for future commercialization.

2022: Resubmission of Clinical Trial Application for Foam Formulation

Overview
Resubmitted clinical trial approval application in China for temperature-controlled foam topical drug hydrocortisone butyrate.
Impact
Expected to improve patient convenience with new dosage form.

2021: Strengthening Medical Device Subsidiary of GNI USA Inc.

Overview
Expanded medical device business by acquiring stake in US Berkeley Advanced Biomaterials LLC.
Impact
Creates new revenue sources beyond pharmaceuticals.

2020: Advanced Clinical Data Analysis Using AI Technology

Overview
Introduced AI-based analysis methods to improve efficiency and accuracy of clinical trials.
Impact
Contributes to shorter development periods and cost reductions.

Sustainability

  • Promoting production process improvements to reduce environmental impact
  • Implementing medical support programs for local communities
  • Introducing green procurement standards and strengthening supply chain management
  • Focusing on employee health and safety
  • Strengthening corporate governance